Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma - Evaluation of T-cell responses by different read-out systems

Haematologica

Volumn 92, Issue 1, 2007, Pages 110-114

  Abdalla, Amir Osman ^a,b   Hansson, Lotta ^a,b   Eriksson, Ingrid ^a,b   Näsman Glaser, Barbro ^b   Rossmann, Eva D ^b   Rabbani, Hodjattallah ^a,b   Mellstedt, Håkan ^a,b   Österborg, Anders ^a,b  

^a Cancer Centre Karolinska   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Idiotype; Myeloma; T cell response; Vaccination

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MULTIPLE MYELOMA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGY; HUMANS; IMMUNOGLOBULIN IDIOTYPES; INTERFERON TYPE II; INTERLEUKIN-12; MIDDLE AGED; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846900685     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10095     Document Type: Article

References (18)

1. Jean WC, Spellman SR, Wallenfriedman MA, Flores CT, Kurtz BP, Hall WA, et al. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J Neurooncol 2004;66:39-49.
2. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM. Sustained IL-12 signaling is required for Th1 development. J Immunol 2004;172:61-9.
3. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
4. Hansson L, Abdalla AO, Rabbani H, Österborg A, Mellstedt H. Idiotype Vaccination combined with IL-12, or IL-12 and GM-CSF, in Early Stage Multiple Myeloma Patients. Blood 2004;104(11)[Abstract 1500].
5. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte- macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998;91:2459-66.
6. Abdalla AO, Kiaii S, Hansson L, Rossmann ED, Jeddi-Tehrani M, Shokri F, et al. Kinetics of cytokine gene expression in human CD4+ and CD8+ T-lymphocyte subsets using quantitative real-time PCR. Scand J Immunol 2003;58:601-6.
7. Mozaffari F, Hansson L, Kiaii S, Ju X, Rossmann ED, Rabbani H, et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004;124:315-24.
8. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
9. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006; 12:2346s-52s.
10. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
11. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35.
12. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88:202-10.
13. Salem ML, Kadima AN, Zhou Y, Nguyen CL, Rubinstein MP, Demcheva M, et al. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol 2004;172:5159-67.
14. Weber JS, Snively J, Sian S, Delto J, Groshen S, Gee C, et al. J Clin Oncol; 2005 ASCO Annual Meeting Proceedings 2005;23(No 16S (June 1 Supplement) [Abstract # 2506].
15. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 1996;93:10972-77.
16. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000;164:3102-11.
17. Speiser DE, Rimoldi D, Batard P, Lienard D, Lejeune F, Cerottini JC, et al. Disease-driven T cell activation predicts immune responses to vaccination against melanoma. Cancer Immun 2003;3:12-9.
18. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004;173:5372-80.